{"id":"cyclophosphamide-injections","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"60-90","effect":"Nausea and vomiting"},{"rate":"40-60","effect":"Alopecia"},{"rate":"5-40","effect":"Hemorrhagic cystitis"},{"rate":"variable","effect":"Infertility"},{"rate":"1-5","effect":"Secondary malignancies"},{"rate":"20-40","effect":"Immunosuppression/infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclophosphamide is a nitrogen mustard derivative that forms reactive intermediates which bind to DNA and create cross-links between DNA strands. This prevents DNA replication and transcription, leading to cell death. It is particularly effective against rapidly dividing cells, including cancer cells and activated lymphocytes, making it useful in both oncology and immunosuppressive applications.","oneSentence":"Cyclophosphamide is an alkylating agent that cross-links DNA strands, preventing cell division and triggering apoptosis in rapidly dividing cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:18.125Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Lymphomas (Hodgkin and non-Hodgkin)"},{"name":"Breast cancer"},{"name":"Ovarian cancer"},{"name":"Leukemias"},{"name":"Multiple myeloma"},{"name":"Severe rheumatoid arthritis (immunosuppressive use)"}]},"trialDetails":[{"nctId":"NCT05702853","phase":"PHASE1, PHASE2","title":"Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2023-11-06","conditions":"B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia","enrollment":27},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT02443077","phase":"PHASE3","title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-10-12","conditions":"Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","enrollment":94},{"nctId":"NCT06767046","phase":"PHASE1","title":"KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Corregene Biotechnology Co., Ltd","startDate":"2025-02-18","conditions":"Colorectal, Pancreatic, Non-small Cell Lung Cancer (NSCLC)","enrollment":8},{"nctId":"NCT07490275","phase":"PHASE1","title":"Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Refractory/Relapsed Systemic Lupus Erythematosus, Refractory / Relapsed / Progressive Systemic Sclerosis, Refractory / Relapsing / Progressive Inflammatory Myopathy","enrollment":9},{"nctId":"NCT07491263","phase":"PHASE1","title":"Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2026-05-01","conditions":"Relapsed/Refractory CD19-positive B-ALL","enrollment":6},{"nctId":"NCT07490041","phase":"EARLY_PHASE1","title":"Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases","status":"RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2026-03-19","conditions":"Rheumatic Diseases, Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese), Systemic Lupus Erythematosus (SLE)","enrollment":36},{"nctId":"NCT07491822","phase":"NA","title":"A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-25","conditions":"TNBC","enrollment":43},{"nctId":"NCT07487402","phase":"EARLY_PHASE1","title":"Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2026-03-30","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":27},{"nctId":"NCT02287311","phase":"PHASE1","title":"Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2015-02","conditions":"Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus","enrollment":38},{"nctId":"NCT06563245","phase":"PHASE2, PHASE3","title":"Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2024-09-25","conditions":"Classical Hodgkin Lymphoma, Child, Adolescent","enrollment":96},{"nctId":"NCT02405676","phase":"PHASE2, PHASE3","title":"BNHL-2015 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2015-01-01","conditions":"Mature B-cell Non-Hodgkin Lymphoma","enrollment":200},{"nctId":"NCT06658951","phase":"NA","title":"Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors","status":"RECRUITING","sponsor":"UTC Therapeutics Inc.","startDate":"2025-04-03","conditions":"HER2-positive Advanced Malignant Solid Tumors","enrollment":30},{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT02845882","phase":"PHASE3","title":"LBL-2016 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2016-01","conditions":"Lymphoblastic Lymphoma","enrollment":150},{"nctId":"NCT05813327","phase":"PHASE1","title":"Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-03-14","conditions":"Soft Tissue Sarcoma, Sts, Sarcoma,Soft Tissue","enrollment":6},{"nctId":"NCT06481735","phase":"PHASE1, PHASE2","title":"TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-02-15","conditions":"Acute Lymphocytic Leukemia","enrollment":30},{"nctId":"NCT04001829","phase":"PHASE2","title":"Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-08-09","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":249},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":"Ovarian Cancer","enrollment":176},{"nctId":"NCT07453446","phase":"PHASE1","title":"Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma","status":"RECRUITING","sponsor":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","startDate":"2025-03-04","conditions":"Relapsed or Refractory Lymphoma","enrollment":18},{"nctId":"NCT07275736","phase":"EARLY_PHASE1","title":"A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases","status":"RECRUITING","sponsor":"Juventas Cell Therapy Ltd.","startDate":"2025-03-01","conditions":"Neurological Autoimmune Diseases","enrollment":18},{"nctId":"NCT03152318","phase":"PHASE1","title":"A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-07-18","conditions":"Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma","enrollment":62},{"nctId":"NCT07449949","phase":"","title":"A Single-Arm Study on the Efficacy of Sequential Chemoradiotherapy Followed by Surgery in Adult Nasal and Paranasal Sinus Rhabdomyosarcoma","status":"ENROLLING_BY_INVITATION","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-10-30","conditions":"ORR, PFS, OS","enrollment":43},{"nctId":"NCT05283720","phase":"PHASE2","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2022-06-14","conditions":"Non-Hodgkin Lymphoma","enrollment":496},{"nctId":"NCT06191744","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-02-05","conditions":"Follicular Lymphoma (FL)","enrollment":1095},{"nctId":"NCT07447726","phase":"PHASE1, PHASE2","title":"Exploratory Clinical Study on the Safety and Efficacy of CD19X CAR-T Cell Injection in the Treatment of Relapsed/Refractory Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-05","conditions":"Large B-Cell Lymphoma (LBCL)","enrollment":3},{"nctId":"NCT06045247","phase":"PHASE2","title":"Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-01-05","conditions":"Large B-cell Lymphoma","enrollment":40},{"nctId":"NCT07416682","phase":"EARLY_PHASE1","title":"CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2026-01-31","conditions":"High-risk Plasma Cell Neoplasms","enrollment":20},{"nctId":"NCT07246096","phase":"EARLY_PHASE1","title":"Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2026-02-20","conditions":"Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Sclerosis","enrollment":60},{"nctId":"NCT05672459","phase":"PHASE1, PHASE2","title":"A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-06-21","conditions":"Solid Tumor","enrollment":31},{"nctId":"NCT07228624","phase":"PHASE2","title":"Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-02-04","conditions":"Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":50},{"nctId":"NCT07421856","phase":"PHASE1, PHASE2","title":"Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.","status":"NOT_YET_RECRUITING","sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","startDate":"2026-02-01","conditions":"Multiple Myeloma in Relapse, Multiple Myeloma Refractory","enrollment":24},{"nctId":"NCT04570423","phase":"PHASE2","title":"A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy","status":"RECRUITING","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2021-05-20","conditions":"Solid Tumors, Lymphoma","enrollment":40},{"nctId":"NCT03909412","phase":"PHASE1","title":"Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2019-10-08","conditions":"Multiple Myeloma","enrollment":18},{"nctId":"NCT06253520","phase":"PHASE1","title":"Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-16","conditions":"Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer","enrollment":210},{"nctId":"NCT07300475","phase":"PHASE1","title":"Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-03-31","conditions":"Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT07406724","phase":"PHASE2","title":"HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Qingdao Sino-Cell Biomedicine Co., Ltd.","startDate":"2026-02-26","conditions":"Melanoma (Excluding Uveal Melanoma)","enrollment":90},{"nctId":"NCT05739409","phase":"NA","title":"LILRB4 STAR-T Cell Therapy for Monocytic Leukemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-02-16","conditions":"Acute Myelogenous Leukemia, Chronic Myelomonocytic Leukemia","enrollment":1},{"nctId":"NCT07400328","phase":"PHASE2","title":"Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-01-15","conditions":"Oral Mucositis, Stomatitis, Gastrointestinal Mucositis","enrollment":22},{"nctId":"NCT06528496","phase":"PHASE2","title":"N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-07-22","conditions":"High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma","enrollment":45},{"nctId":"NCT06009627","phase":"PHASE2, PHASE3","title":"Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-11","conditions":"Breast Cancer","enrollment":119},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT05753618","phase":"PHASE4","title":"Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2023-04-17","conditions":"Early-stage Breast Cancer","enrollment":242},{"nctId":"NCT01516580","phase":"PHASE3","title":"Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2011-12","conditions":"B-cell Non Hodgkin Lymphoma, Mature B-cell Leukemia Burkitt-type","enrollment":482},{"nctId":"NCT01516567","phase":"PHASE2","title":"Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2012-04-01","conditions":"Primary Mediastinal Large B Cell Lymphoma","enrollment":47},{"nctId":"NCT07388602","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)","status":"RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2026-01-08","conditions":"Amyloidosis","enrollment":90},{"nctId":"NCT06564038","phase":"PHASE1, PHASE2","title":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-01-30","conditions":"Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma","enrollment":276},{"nctId":"NCT07283315","phase":"EARLY_PHASE1","title":"Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases","status":"RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2025-12-03","conditions":"Paediatric B Cell-related Autoimmune Diseases, Autoimmune Diseases, CAR","enrollment":12},{"nctId":"NCT06549296","phase":"EARLY_PHASE1","title":"Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases","status":"SUSPENDED","sponsor":"Nanjing Bioheng Biotech Co., Ltd.","startDate":"2024-09-13","conditions":"Systemic Lupus Erythematosus, Systemic Sclerosis, ANCA Associated Vasculitis","enrollment":12},{"nctId":"NCT06775912","phase":"EARLY_PHASE1","title":"Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases","status":"RECRUITING","sponsor":"Nanjing Bioheng Biotech Co., Ltd.","startDate":"2025-01-03","conditions":"SLE, Systemic Sclerosis, IIM","enrollment":18},{"nctId":"NCT07011004","phase":"PHASE1","title":"A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-05-30","conditions":"Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse","enrollment":18},{"nctId":"NCT06829771","phase":"PHASE1, PHASE2","title":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-23","conditions":"Diffuse Large B Cell Lymphoma","enrollment":90},{"nctId":"NCT07372079","phase":"PHASE2","title":"Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-04-05","conditions":"Breast Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitors","enrollment":40},{"nctId":"NCT06462144","phase":"EARLY_PHASE1","title":"IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy","status":"TERMINATED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-06-13","conditions":"Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathy (IIM)","enrollment":3},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT07367685","phase":"PHASE1","title":"Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"The Second Affiliated Hospital of Fujian Medical University","startDate":"2026-05-01","conditions":"Recurrent/Refractory B-cell Lymphoma","enrollment":6},{"nctId":"NCT06252870","phase":"PHASE2","title":"Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-07-18","conditions":"Graft Versus Host Disease, Hematologic Malignancy","enrollment":82},{"nctId":"NCT07366658","phase":"PHASE1","title":"Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-20","conditions":"SCLC, Extensive Stage, Neuroendocrine Tumors","enrollment":9},{"nctId":"NCT00902044","phase":"PHASE1","title":"Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2010-02-11","conditions":"Sarcoma","enrollment":36},{"nctId":"NCT01175356","phase":"PHASE1","title":"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2011-12-21","conditions":"Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma","enrollment":99},{"nctId":"NCT01953900","phase":"PHASE1","title":"iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2014-04","conditions":"Osteosarcoma, Neuroblastoma","enrollment":26},{"nctId":"NCT03642626","phase":"PHASE2","title":"MT2017-45: CAR-T Cell Therapy for Heme Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-12-18","conditions":"Acute Lymphoblastic Leukemia, Large B-cell Lymphoma","enrollment":150},{"nctId":"NCT07362914","phase":"PHASE3","title":"Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-07","conditions":"Breast Cancer","enrollment":182},{"nctId":"NCT07337785","phase":"EARLY_PHASE1","title":"CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases","status":"RECRUITING","sponsor":"Daishi Tian","startDate":"2025-12-12","conditions":"Relapsing or Refractory Multiple Sclerosis (MS), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","enrollment":36},{"nctId":"NCT05868915","phase":"PHASE1","title":"HV-101 for Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Hervor Therapeutics","startDate":"2023-08-04","conditions":"Advanced Solid Tumors","enrollment":1},{"nctId":"NCT06513364","phase":"PHASE1","title":"Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer","status":"COMPLETED","sponsor":"Beijing Wehand-Bio Pharmaceutical Co., Ltd","startDate":"2024-09-10","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT05250973","phase":"PHASE2","title":"A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-03-01","conditions":"Amyloidosis","enrollment":151},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT07294872","phase":"PHASE1","title":"A Study of TIL in Advanced Solid Tumors (CZ)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2026-05-08","conditions":"Solid Tumor, Adult","enrollment":30},{"nctId":"NCT07342738","phase":"EARLY_PHASE1","title":"TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"KRAS G12V, KRAS G12D, Solid Tumor","enrollment":25},{"nctId":"NCT04392648","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","status":"WITHDRAWN","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2020-06-24","conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":""},{"nctId":"NCT04770272","phase":"PHASE2","title":"Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy","status":"TERMINATED","sponsor":"Palleos Healthcare GmbH","startDate":"2021-03-01","conditions":"Triple-negative Breast Cancer","enrollment":442},{"nctId":"NCT05634785","phase":"PHASE2","title":"CD30 CAR for CD30+ NSGCT","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2022-12-09","conditions":"Germ Cell Tumor, Nonseminomatous Germ Cell Tumor","enrollment":2},{"nctId":"NCT03571321","phase":"PHASE1","title":"Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2019-05-28","conditions":"Acute Lymphoblastic Leukemia, ALL, Childhood, ALL","enrollment":15},{"nctId":"NCT06898385","phase":"PHASE1","title":"A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-03-27","conditions":"Pancreatic Cancer","enrollment":9},{"nctId":"NCT02870907","phase":"PHASE2","title":"Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Curie","startDate":"2010-03-18","conditions":"Retinoblastoma","enrollment":195},{"nctId":"NCT06692452","phase":"PHASE2","title":"Tazemetostat Plus CHOP in 1L T-cell Lymphoma","status":"SUSPENDED","sponsor":"Eric Jacobsen, MD","startDate":"2024-12-24","conditions":"Lymphoma, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":24},{"nctId":"NCT06861244","phase":"PHASE2","title":"Embryonal Tumor With Multilayered Rosettes","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-03-06","conditions":"Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos","enrollment":70},{"nctId":"NCT01746849","phase":"PHASE2","title":"Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":"Leukemia, Multiple Myeloma, Myelodysplastic Syndrome","enrollment":82},{"nctId":"NCT06514768","phase":"EARLY_PHASE1","title":"JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"920th Hospital of Joint Logistics Support Force of People's Liberation Army of China","startDate":"2024-06-20","conditions":"B-cell Acute Lymphoblastic Leukemia (B-ALL)","enrollment":20},{"nctId":"NCT04872985","phase":"PHASE2","title":"Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-20","conditions":"Breast Cancer, Hormone-receptor Positive Breast Cancer","enrollment":140},{"nctId":"NCT06072612","phase":"PHASE3","title":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","status":"RECRUITING","sponsor":"BriaCell Therapeutics Corporation","startDate":"2023-12-05","conditions":"Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm","enrollment":404},{"nctId":"NCT07317778","phase":"PHASE2","title":"Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-15","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer","enrollment":249},{"nctId":"NCT07315503","phase":"EARLY_PHASE1","title":"An Open-label Study of GC012F in Rheumatoid Arthritis.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-01-15","conditions":"Rheumatoid Arthritis","enrollment":9},{"nctId":"NCT07306156","phase":"PHASE1, PHASE2","title":"GP350 CAR-T for Relapse/Refractory and Epstein-Barr Virus Infection Associated Lymphoid Neoplasms","status":"RECRUITING","sponsor":"Zhimin Zhai","startDate":"2025-11-10","conditions":"EBV Associated Lymphoid Neoplasms","enrollment":24},{"nctId":"NCT03983850","phase":"PHASE1, PHASE2","title":"Optimizing PTCy Dose and Timing","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-09","conditions":"Graft Versus Host Disease, Hematologic Neoplasms","enrollment":105},{"nctId":"NCT06626256","phase":"PHASE1","title":"STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2025-12-05","conditions":"Locally Advanced Cervical Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Malignant Solid Neoplasm","enrollment":""},{"nctId":"NCT07301164","phase":"EARLY_PHASE1","title":"Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-12-11","conditions":"System Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myositis","enrollment":10},{"nctId":"NCT07301138","phase":"PHASE2","title":"BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-12-15","conditions":"Acute Lymphoblastic Leukemia","enrollment":23},{"nctId":"NCT06828328","phase":"EARLY_PHASE1","title":"A Study of GC203 TIL in PDCA (RJ)","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2025-02-10","conditions":"Pancreatic Cancer, Pancratic Ductal Adenocarcinoma, Treatment Side Effects","enrollment":10},{"nctId":"NCT04960072","phase":"EARLY_PHASE1","title":"A Study of GC101 TIL in r/r Gastrointestinal Tumors (10hospital)","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2021-06-30","conditions":"Gastrointestinal Tumor","enrollment":50},{"nctId":"NCT05457556","phase":"PHASE3","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-03-15","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":435},{"nctId":"NCT05115630","phase":"PHASE2","title":"Off-the-shelf NK Cells + SCT for Myeloid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-04-08","conditions":"Myeloid Malignancies, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":24},{"nctId":"NCT06488950","phase":"EARLY_PHASE1","title":"A Study of TIL in Advanced Solid Tumors (DFGD)","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2023-04-01","conditions":"Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects","enrollment":30},{"nctId":"NCT06546150","phase":"PHASE1","title":"RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-03-01","conditions":"KRAS G12D, T Cell Therapy","enrollment":30},{"nctId":"NCT07153068","phase":"PHASE1, PHASE2","title":"SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-06-28","conditions":"T Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia (AML)","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cyclophosphamide injections","genericName":"Cyclophosphamide injections","companyName":"Astellas Pharma China, Inc.","companyId":"astellas-pharma-china-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclophosphamide is an alkylating agent that cross-links DNA strands, preventing cell division and triggering apoptosis in rapidly dividing cells. Used for Lymphomas (Hodgkin and non-Hodgkin), Breast cancer, Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}